Huimin Geng

List of Publications by Year
in descending order

149 papers	5,016 citations	94381 37 h-index	98753 67 g-index
157 all docs	157 docs citations	157 times ranked	8842 citing authors

#	Article	IF	Citations
1	Polymorphic transient glycolipid assemblies with tunable lifespan and cargo release. Journal of Colloid and Interface Science, 2022, 610, 1067-1076.	5.0	2
2	Hot Melt Super Glue: Multi‐Recyclable Polyphenol‐Based Supramolecular Adhesives. Macromolecular Rapid Communications, 2022, 43, e2100830.	2.0	19
3	Principles of Cation‐π Interactions for Engineering Mussel-Inspired Functional Materials. Accounts of Chemical Research, 2022, 55, 1171-1182.	7.6	42
4	Metal Ion-Directed Functional Metal–Phenolic Materials. Chemical Reviews, 2022, 122, 11432-11473.	23.0	108
5	Convergent architecting of multifunction-in-one hydrogels as wound dressings for surgical anti-infections. Materials Today Chemistry, 2022, 25, 100968.	1.7	10
6	H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. Leukemia, 2021, 35, 90-106.	3.3	35
7	Tumor metabolism and neurocognition in CNS lymphoma. Neuro-Oncology, 2021, 23, 1668-1679.	0.6	9
8	PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	10
9	Surface Proteomics Reveals CD72 as a Target for *In Vitro*–Evolved Nanobody-Based CAR-T Cells in *KMT2A/MLL1*-Rearranged B-ALL. Cancer Discovery, 2021, 11, 2032-2049.	7.7	37
10	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, 2021, 12, 5337.	5.8	14
11	Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. Blood, 2021, 138, 616-616.	0.6	1
12	Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation. Blood, 2021, 138, 792-792.	0.6	0
13	BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells. Blood, 2021, 138, 359-359.	0.6	2
14	Functional Multi-Omics Reveals Genetic and Pharmacologic Regulation of Surface CD38 in Multiple Myeloma. Blood, 2021, 138, 2648-2648.	0.6	0
15	Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies. Blood, 2021, 138, 355-355.	0.6	0
16	Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2021, 22, 12167.	1.8	9
17	DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia, 2020, 34, 938-941.	3.3	24
18	Human pediatric B-cell acute lymphoblastic leukemias can be classified as B-1 or B-2-like based on a minimal transcriptional signature. Experimental Hematology, 2020, 90, 65-71.e1.	0.2	7

#	Article	IF	Citations
19	Signalling input from divergent pathways subverts Bâcell transformation. Nature, 2020, 583, 845-851.	13.7	37
20	BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis. Nature Genetics, 2020, 52, 1384-1396.	9.4	57
21	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in Bâcells. Nature, 2020, 588, 491-497.	13.7	57
22	Interfacial Assembly of Metalâ€"Phenolic Networks for Hair Dyeing. ACS Applied Materials & Interfaces, 2020, 12, 29826-29834.	4.0	18
23	E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia. Blood, 2020, 136, 11-23.	0.6	33
24	The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias. Genes and Immunity, 2020, 21, 119-130.	2.2	7
25	Injectable and Sprayable Polyphenol-Based Hydrogels for Controlling Hemostasis. ACS Applied Bio Materials, 2020, 3, 1258-1266.	2.3	66
26	Integrin Î±6 mediates the drug resistance of acute lymphoblastic B-cell leukemia. Blood, 2020, 136, 210-223.	0.6	31
27	Survival and Patient-Reported Outcomes of Older Adults with Primary Central Nervous System Lymphoma on Low-Dose Lenalidomide. Blood, 2020, 136, 21-22.	0.6	1
28	Rationale for targeting BCL6 in <i>MLL</i>-rearranged acute lymphoblastic leukemia. Genes and Development, 2019, 33, 1265-1279.	2.7	17
29	Lowâ€dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. British Journal of Haematology, 2019, 186, 180-183.	1.2	31
30	Polyphenol-Based Particles for Theranostics. Theranostics, 2019, 9, 3170-3190.	4.6	123
31	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nature Immunology, 2019, 20, 86-96.	7.0	71
32	In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies. Blood, 2019, 134, 1337-1337.	0.6	8
33	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. Blood, 2019, 134, 393-393.	0.6	0
34	Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL. Blood, 2019, 134, 3785-3785.	0.6	0
35	Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation. Blood, 2019, 134, 3944-3944.	0.6	0
36	Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis. Blood, 2019, 134, 2782-2782.	0.6	1

#	Article	IF	Citations
37	Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies. Blood, 2019, 134, 1494-1494.	0.6	0
38	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. Blood, 2019, 134, 1239-1239.	0.6	0
39	Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions. Blood, 2019, 134, 746-746.	0.6	1
40	Lgr5 Functions As a Critical Negative Regulator of Wnt/Î²-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation. Blood, 2019, 134, 748-748.	0.6	0
41	Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2836-2841.	3.3	44
42	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell, 2018, 173, 470-484.e18.	13.5	89
43	Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Advances, 2018, 2, 1595-1607.	2.5	143
44	CAMKs support development of acute myeloid leukemia. Journal of Hematology and Oncology, 2018, 11, 30.	6.9	26
45	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood, 2018, 132, 2026-2039.	0.6	48
46	Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma. Blood, 2018, 132, 4230-4230.	0.6	1
47	Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies. Blood, 2018, 132, 547-547.	0.6	3
48	Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia. Blood, 2018, 132, 568-568.	0.6	0
49	IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation. Blood, 2018, 132, 552-552.	0.6	2
50	Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFĸB Activation in Preclinical Patient-Derived Models of CNS Lymphoma. Blood, 2018, 132, 2840-2840.	0.6	0
51	CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies. Blood, 2018, 132, 776-776.	0.6	0
52	Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling. Blood, 2018, 132, 1336-1336.	0.6	0
53	MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27Âacetylation. Experimental Hematology, 2017, 47, 64-75.	0.2	25
54	MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. Cell Reports, 2017, 18, 482-495.	2.9	69

#	Article	IF	Citations
55	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discovery, 2017, 7, 506-521.	7.7	43
56	Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre‐B ALL. Journal of Experimental Medicine, 2017, 214, 793-814.	4.2	34
57	Metabolic gatekeeper function of B-lymphoid transcription factors. Nature, 2017, 542, 479-483.	13.7	175
58	Ultrasound-induced gelation of fluorenyl-9-methoxycarbonyl-l-lysine(fluorenyl-9-methoxycarbonyl)-OH and its dipeptide derivatives showing very low minimum gelation concentrations. Journal of Colloid and Interface Science, 2017, 490, 665-676.	5.0	17
59	Synthesis and gelation capability of mono- and disubstituted cyclo(L-Glu-L-Glu) derivatives with tyramine, tyrosine and phenylalanine. Colloid and Polymer Science, 2017, 295, 1549-1561.	1.0	9
60	<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery, 2017, 7, 38-53.	7.7	218
61	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nature Communications, 2017, 8, 2127.	5.8	75
62	Synthesis and gelation capability of Fmoc and Boc mono-substituted cyclo(L-Lys-L-Lys)s. Chemical Research in Chinese Universities, 2016, 32, 484-492.	1.3	6
63	Low-Molecular-Weight Organo- and Hydrogelators Based on Cyclo(<scp>l</scp>-Lys-<scp>l</scp>-Glu). Langmuir, 2016, 32, 4586-4594.	1.6	44
64	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine, 2016, 22, 379-387.	15.2	94
65	Gelation capability of cysteine-modified cyclo(L-Lys-L-Lys)s dominated by Fmoc and Trt protecting groups. Science China Chemistry, 2016, 59, 293-302.	4.2	7
66	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. Journal of Clinical Investigation, 2016, 126, 3351-3362.	3.9	133
67	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. Blood, 2016, 128, 4088-4088.	0.6	2
68	Targeting NF-κB Activation in Novel Intracranial Models of CNS Lymphoma. Blood, 2016, 128, 777-777.	0.6	2
69	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. Blood, 2016, 128, 735-735.	0.6	0
70	Identification of IRF8 As a Potent Tumor Suppressor in Murine Acute Promyelocytic Leukemia. Blood, 2016, 128, 1518-1518.	0.6	0
71	Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism. Blood, 2016, 128, 4069-4069.	0.6	1
72	Genetic Subtypes of Human Pediatric ALLs Show Gene Expression Differences That Parallel Those Observed in Mouse B1 and B2 Progenitors, Suggesting Divergent Developmental Origins. Blood, 2016, 128, 1741-1741.	0.6	0

#	Article	IF	Citations
73	IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies. Blood, 2016, 128, 2738-2738.	0.6	0
74	Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2771-2771.	0.6	0
75	Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation. Blood, 2016, 128, 437-437.	0.6	0
76	PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia. Blood, 2016, 128, 1056-1056.	0.6	1
77	BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. Blood, 2016, 128, 438-438.	0.6	0
78	Deregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph+ leukemia. Experimental Hematology and Oncology, 2015, 5, 5.	2.0	1
79	Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nature Immunology, 2015, 16, 766-774.	7.0	163
80	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports, 2015, 13, 2715-2727.	2.9	118
81	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 27, 409-425.	7.7	109
82	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28, 114-128.	7.7	107
83	TET1 is a tumor suppressor of hematopoietic malignancy. Nature Immunology, 2015, 16, 653-662.	7.0	173
84	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature, 2015, 521, 357-361.	13.7	127
85	Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nature Communications, 2015, 6, 6471.	5.8	41
86	IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL Cells. Blood, 2015, 126, 1325-1325.	0.6	2
87	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1434-1434.	0.6	6
88	Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3900-3900.	0.6	4
89	A Study on Synthesis and Gelation Capability of Fmoc and Boc Disubstituted Cyclo(L-Lys-L-Lys)s. Acta Chimica Sinica, 2015, 73, 423.	0.5	6
90	Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3716-3716.	0.6	0

#	Article	IF	Citations
91	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. Blood, 2015, 126, 556-556.	0.6	0
92	PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 902-902.	0.6	0
93	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2219-28.	3.3	78
94	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood, 2014, 123, 1699-1708.	0.6	83
95	RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction. Cell Reports, 2013, 3, 116-127.	2.9	130
96	SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood, 2013, 121, 148-155.	0.6	61
97	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature Medicine, 2013, 19, 1014-1022.	15.2	100
98	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. PLoS Genetics, 2013, 9, e1003137.	1.5	102
99	A TAF4 coactivator function for E proteins that involves enhanced TFIID binding. Genes and Development, 2013, 27, 1596-1609.	2.7	30
100	Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood, 2013, 121, 1814-1818.	0.6	102
101	Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALL. Blood, 2013, 122, 2505-2505.	0.6	5
102	Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B Cells. Blood, 2013, 122, 2506-2506.	0.6	1
103	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. Blood, 2013, 122, 3736-3736.	0.6	1
104	Global Methylation Analysis Reveals Novel Candidate Tumor Suppressor Genes In Natural Killer Cell Lymphomas. Blood, 2013, 122, 1262-1262.	0.6	0
105	Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia. Blood, 2013, 122, 349-349.	0.6	1
106	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. Blood, 2013, 122, 229-229.	0.6	0
107	Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1250-1250.	0.6	0
108	The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL. Blood, 2013, 122, 836-836.	0.6	0

#	Article	IF	Citations
109	Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. Blood, 2013, 122, 72-72.	0.6	0
110	Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia. Cancer Discovery, 2012, 2, 1004-1023.	7.7	80
111	Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL. Blood, 2012, 120, 872-872.	0.6	1
112	SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic Leukemia. Blood, 2012, 120, 863-863.	0.6	0
113	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. Blood, 2012, 120, 1300-1300.	0.6	0
114	Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL.. Blood, 2012, 120, 2563-2563.	0.6	0
115	Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. Blood, 2012, 120, 1352-1352.	0.6	1
116	BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid Leukemia. Blood, 2012, 120, 1301-1301.	0.6	2
117	ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL. Blood, 2012, 120, 291-291.	0.6	5
118	Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast Crisis. Blood, 2012, 120, 34-34.	0.6	0
119	Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.. Blood, 2012, 120, 2565-2565.	0.6	0
120	Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL. Blood, 2012, 120, 874-874.	0.6	0
121	Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL. Blood, 2012, 120, 528-528.	0.6	17
122	Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 519-519.	0.6	2
123	Pre-B cell receptor–mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood, 2011, 118, 4174-4178.	0.6	58
124	BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition. Nature, 2011, 473, 384-388.	13.7	174
125	Virtual CGH: an integrative approach to predict genetic abnormalities from gene expression microarray data applied in lymphoma. BMC Medical Genomics, 2011, 4, 32.	0.7	6
126	DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival. Blood, 2011, 118, 1479-1479.	0.6	1

#	Article	IF	Citations
127	Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias. Blood, 2011, 118, 1382-1382.	0.6	0
128	Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. Blood, 2011, 118, 1406-1406.	0.6	0
129	Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes,. Blood, 2011, 118, 3725-3725.	0.6	11
130	BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. Blood, 2011, 118, 562-562.	0.6	0
131	Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood, 2010, 115, 1026-1036.	0.6	353
132	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood, 2010, 116, 5247-5255.	0.6	262
133	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood, 2010, 116, e81-e89.	0.6	138
134	Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia. Blood, 2010, 116, 852-852.	0.6	5
135	A Computational Method to Predict DNA Copy Number Alterations from Gene Expression Data in Tumor Cases. , 2009, , .		1
136	EZH2 Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis.. Blood, 2009, 114, 3465-3465.	0.6	2
137	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.. Blood, 2009, 114, 619-619.	0.6	10
138	Message Passing Clustering (MPC): a knowledge-based framework for clustering under biological constraints. International Journal of Data Mining and Bioinformatics, 2008, 2, 95.	0.1	7
139	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.. Blood, 2008, 112, 2049-2049.	0.6	0
140	Molecular Signatures to Improve Diagnosis, Prognostication and Identification of Oncogenic Pathways in Peripheral T and NK Cell Lymphoma.. Blood, 2008, 112, 3339-3339.	0.6	4
141	Virtual CGH: Prediction of Novel Regions of Chromosomal Alterations in Tumor from Gene Expression Profiling. , 2007, , .		0
142	Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways. BMC Genomics, 2007, 8, 230.	1.2	82
143	Cross-platform analysis of cancer biomarkers: a Bayesian network approach to incorporating mass spectrometry and microarray data. Cancer Informatics, 2007, 3, 183-202.	0.9	5
144	Analysis of Gene Expression Patterns and Gene Copy Number Changes in Human NK Cell Malignancies.. Blood, 2006, 108, 2228-2228.	0.6	0

#	Article	IF	Citations
145	Learning yeast gene functions from heterogeneous sources of data using hybrid weighted Bayesian networks. , 2005, , 25-34.		4
146	A new approach to clustering biological data using message passing. , 0, , .		2
147	Mining Gene Microarray Data with Adaptive Feature Scaling. , 0, , .		1
148	A New Clustering Algorithm Using Message Passing and its Applications in Analyzing Microarray Data. , 0, , .		8
149	On Clustering Biological Data Using Unsupervised and Semi-Supervised Message Passing. , 0, , .		3